NCT05642026 INTERCOSTAL NERVE BLOCK: Efficacy of CINB for Patients With Multiple Rib Fractures
| NCT ID | NCT05642026 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Zachary Warriner |
| Condition | Rib Fractures |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2025-09-23 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 180 participants in total. It began in 2025-09-23 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, randomized, non-blinded study comparing CINB plus medical therapy versus standard medical care (non-steroidals and opioids intravenous/oral inpatient and oral outpatient) alone for patients with multiple rib fractures. The objective of this study is to analyze the effect of continuous intercostal nerve block (CINB) in the treatment of patients admitted to the adult trauma service with rib fractures. The effectiveness of CINB as adjunctive treatment will be compared to standard medical therapy involving nonsteroidal and intravenous/oral opioid medications.
Eligibility Criteria
Inclusion Criteria: * Subjects will be at least 18 years old * Subjects will have 2 or more identified rib fractures * Subjects will be willing to provide informed consent for procedure * Subjects will be identified as appropriate for initiation of continuous nerve block therapy for treatment of rib fracture associated pain. Exclusion Criteria: * Documented allergy to study medication * Epidural catheter use * Prisoners * Refusal of CINB therapy
Contact & Investigator
Zachary Warriner, MD
PRINCIPAL INVESTIGATOR
University of Kentucky
Frequently Asked Questions
Who can join the NCT05642026 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rib Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05642026 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05642026 currently recruiting?
Yes, NCT05642026 is actively recruiting participants. Visit ClinicalTrials.gov or contact Zachary Warriner to inquire about joining.
Where is the NCT05642026 trial being conducted?
This trial is being conducted at Lexington, United States.
Who is sponsoring the NCT05642026 clinical trial?
NCT05642026 is sponsored by Zachary Warriner. The principal investigator is Zachary Warriner, MD at University of Kentucky. The trial plans to enroll 180 participants.